Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06360094




Registration number
NCT06360094
Ethics application status
Date submitted
8/04/2024
Date registered
11/04/2024
Date last updated
19/11/2024

Titles & IDs
Public title
A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
Scientific title
A Phase IIa/IIb, Randomised, Double Blind, Placebo-controlled, Parallel-group Dose-finding Study to Examine the Efficacy and Safety of BI 1839100 Administered Orally Over a 12-week Treatment Period in Patients With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis With Clinically Meaningful Cough
Secondary ID [1] 0 0
2023-510249-79-00
Secondary ID [2] 0 0
1490-0004
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Idiopathic Pulmonary Fibrosis 0 0
Progressive Pulmonary Fibrosis 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Inflammatory and Immune System 0 0 0 0
Connective tissue diseases
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - BI 1839100
Treatment: Drugs - Placebo

Placebo comparator: Phase IIa/IIb, IPF cohort: Placebo -

Experimental: Phase IIa/IIb, IPF cohort: BI 1839100 low dose -

Experimental: Phase IIa/IIb, IPF cohort: BI 1839100 medium dose -

Experimental: Phase IIa/IIb, IPF cohort: BI 1839100 high dose -

Placebo comparator: Phase IIb, PPF cohort: Placebo -

Experimental: Phase IIb, PPF cohort: BI 1839100 high dose -


Treatment: Drugs: BI 1839100
BI 1839100

Treatment: Drugs: Placebo
Placebo
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
IPF cohort - Phase IIa: Change from baseline in 24-h cough frequency (Cough count (CC)/h)
Timepoint [1] 0 0
At baseline, at week 4
Primary outcome [2] 0 0
IPF cohort - Phase IIb: Change from baseline in 24-h cough frequency (CC/h)
Timepoint [2] 0 0
At baseline, at week 12
Secondary outcome [1] 0 0
IPF cohort - Phase IIa: Absolute change from baseline in Cough Severity Numerical rating scale (NRS) score
Timepoint [1] 0 0
At baseline, at week 4
Secondary outcome [2] 0 0
IPF cohort - Phase IIa: Absolute change from baseline in Cough Severity Visual analogue scale (VAS) score (mm)
Timepoint [2] 0 0
At baseline, at week 4
Secondary outcome [3] 0 0
IPF cohort - Phase IIb: Cough responder status, defined as a =30% reduction in 24-h cough frequency (CC/h)
Timepoint [3] 0 0
At baseline, at week 12
Secondary outcome [4] 0 0
IPF cohort - Phase IIb: Absolute change from baseline in Forced vital capacity (FVC) (mL)
Timepoint [4] 0 0
At baseline, at week 12
Secondary outcome [5] 0 0
IPF cohort - Phase IIb: Absolute change from baseline in Cough Severity NRS score
Timepoint [5] 0 0
At baseline, at week 12
Secondary outcome [6] 0 0
IPF cohort - Phase IIb: Absolute change from baseline in Cough Severity VAS score (mm)
Timepoint [6] 0 0
At baseline, at week 12
Secondary outcome [7] 0 0
IPF cohort - Phase IIb: Absolute change from baseline in Living with Pulmonary Fibrosis (L-PF) symptom cough domain score
Timepoint [7] 0 0
At baseline, at week 12
Secondary outcome [8] 0 0
IPF cohort - Phase IIb: Absolute change from baseline in Leicester Cough Questionnaire (LCQ) physical domain score
Timepoint [8] 0 0
At baseline, at week 12

Eligibility
Key inclusion criteria
Inclusion Criteria

For Idiopathic Pulmonary Fibrosis (IPF) cohort:

* Minimum age: 40 years
* Diagnosis of IPF
* Chronic cough (>8 weeks prior to Visit 1) attributed to IPF and refractory to treatment for known causes (Principal Investigator (PI) assessment)
* Cough Severity visual analogue scale (VAS) =30 mm at Visit 1 and Visit 2B
* Forced vital capacity (FVC) =45% of predicted normal at Visit 1
* Diffusing capacity of the lungs for carbon monoxide (DLCO) >25% of predicted normal at Visit 1
* Patients may be either:

* On stable therapy with nintedanib or pirfenidone for =12 weeks prior to Visit 1 and are planning to stay on this background treatment for the whole trial duration. Combination of nintedanib plus pirfenidone will not be allowed
* Not on therapy with nintedanib or pirfenidone for =12 weeks prior to Visit 1 (either antifibrotic (AF)-treatment naïve or previously discontinued) and do not plan to start or re-start AF treatment during the trial. It is not permitted to delay nintedanib or pirfenidone therapy for the purpose of participating in this trial
* Patients aged =40 years when signing the informed consent

For Progressive Pulmonary Fibrosis (PPF) cohort:

* Minimum age: 18 years
* Diagnosis of PPF
* Chronic cough (>8 weeks prior to Visit 1) attributed to PPF, refractory to treatment for known causes (PI assessment)
* Cough Severity VAS =30 mm at Visit 1 and Visit 2B
* FVC =45% of predicted normal at Visit 1
* DLCO =25% of predicted normal at Visit 1
* If receiving immunomodulatory therapy for interstitial lung disease (ILD), allowed medications include tacrolimus, mycophenolate mofetil, or azathioprine (stable dose for 12 weeks prior to Visit 1)
* Patients may be either:

* On a stable therapy with nintedanib for =12 weeks prior to Visit 1 and are planning to stay on this background treatment for the whole trial duration
* Not on a therapy with nintedanib for =12 weeks prior to Visit 1 (either AF-treatment naïve or previously discontinued) and do not plan to start or re-start AF treatment during the trial. It is not permitted to delay nintedanib or pirfenidone therapy for the purpose of participating in this trial
* Patients aged >18 years when signing the informed consent Further inclusion criteria apply.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria for IPF and PPF cohorts:

* Acute exacerbation of IPF/PPF within 12 weeks prior to Visit 1
* Forced expiratory volume in 1 second (Forced expiratory volume in 1 second (FEV1))/FVC <0.7 at Visit 1
* Known reversible airflow obstruction/response to bronchodilators
* In the opinion of the Investigator, other clinically significant pulmonary abnormalities, including primary bronchitic and bronchiectatic disorder
* Upper or lower respiratory tract infection within 4 weeks prior to Visit 1
* Ongoing chronic pulmonary infection (e.g. mycobacterial or fungal disease)
* Current smokers (tobacco use within the 6 months prior to Visit 1)
* Initiation or change in supplemental oxygen requirement during 4 weeks prior to Visit 1 Further exclusion criteria apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
28/08/2024
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
6/08/2025
Actual
Sample size
Target
230
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT,NSW,TAS,VIC,WA
Recruitment hospital [1] 0 0
Canberra Hospital - Canberra
Recruitment hospital [2] 0 0
Royal Prince Alfred Hospital - Camperdown, Sydney
Recruitment hospital [3] 0 0
Macquarie University - Macquarie Park
Recruitment hospital [4] 0 0
Launceston Respiratory & Sleep Centre - Launceston
Recruitment hospital [5] 0 0
Lung Research Victoria - Footscray
Recruitment hospital [6] 0 0
Institute for Respiratory Health - Nedlands
Recruitment postcode(s) [1] 0 0
2605 - Canberra
Recruitment postcode(s) [2] 0 0
2050 - Camperdown, Sydney
Recruitment postcode(s) [3] 0 0
2109 - Macquarie Park
Recruitment postcode(s) [4] 0 0
7250 - Launceston
Recruitment postcode(s) [5] 0 0
3011 - Footscray
Recruitment postcode(s) [6] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Massachusetts
Country [6] 0 0
United States of America
State/province [6] 0 0
Nevada
Country [7] 0 0
United States of America
State/province [7] 0 0
New York
Country [8] 0 0
United States of America
State/province [8] 0 0
North Carolina
Country [9] 0 0
United States of America
State/province [9] 0 0
Oklahoma
Country [10] 0 0
United States of America
State/province [10] 0 0
Pennsylvania
Country [11] 0 0
United States of America
State/province [11] 0 0
Rhode Island
Country [12] 0 0
United States of America
State/province [12] 0 0
South Carolina
Country [13] 0 0
United States of America
State/province [13] 0 0
Texas
Country [14] 0 0
United States of America
State/province [14] 0 0
Utah
Country [15] 0 0
Argentina
State/province [15] 0 0
C.a.b.a
Country [16] 0 0
Argentina
State/province [16] 0 0
Caba
Country [17] 0 0
Argentina
State/province [17] 0 0
Capital Federal
Country [18] 0 0
Austria
State/province [18] 0 0
Graz
Country [19] 0 0
Austria
State/province [19] 0 0
Linz
Country [20] 0 0
Austria
State/province [20] 0 0
Vienna
Country [21] 0 0
Austria
State/province [21] 0 0
Wels
Country [22] 0 0
Belgium
State/province [22] 0 0
Bruxelles
Country [23] 0 0
Belgium
State/province [23] 0 0
Gent
Country [24] 0 0
Belgium
State/province [24] 0 0
Liège
Country [25] 0 0
Brazil
State/province [25] 0 0
Barra Mansa
Country [26] 0 0
Brazil
State/province [26] 0 0
Botucatu
Country [27] 0 0
Brazil
State/province [27] 0 0
Goiania
Country [28] 0 0
Brazil
State/province [28] 0 0
Porto Alegre
Country [29] 0 0
Brazil
State/province [29] 0 0
Sao Bernardo do Campo
Country [30] 0 0
Brazil
State/province [30] 0 0
Sao Paulo
Country [31] 0 0
Brazil
State/province [31] 0 0
São Paulo
Country [32] 0 0
Canada
State/province [32] 0 0
British Columbia
Country [33] 0 0
Canada
State/province [33] 0 0
Ontario
Country [34] 0 0
China
State/province [34] 0 0
Beijing
Country [35] 0 0
China
State/province [35] 0 0
Hangzhou
Country [36] 0 0
China
State/province [36] 0 0
Hefei
Country [37] 0 0
China
State/province [37] 0 0
Nanjing
Country [38] 0 0
China
State/province [38] 0 0
Shanghai
Country [39] 0 0
China
State/province [39] 0 0
Shenyang
Country [40] 0 0
China
State/province [40] 0 0
Tianjin
Country [41] 0 0
Finland
State/province [41] 0 0
Oulu
Country [42] 0 0
France
State/province [42] 0 0
Angers
Country [43] 0 0
France
State/province [43] 0 0
Bobigny
Country [44] 0 0
France
State/province [44] 0 0
La Tronche
Country [45] 0 0
France
State/province [45] 0 0
Lille
Country [46] 0 0
France
State/province [46] 0 0
Marseille
Country [47] 0 0
France
State/province [47] 0 0
Nantes
Country [48] 0 0
France
State/province [48] 0 0
Paris
Country [49] 0 0
France
State/province [49] 0 0
Pessac
Country [50] 0 0
France
State/province [50] 0 0
Rouen
Country [51] 0 0
France
State/province [51] 0 0
Tours
Country [52] 0 0
Germany
State/province [52] 0 0
Berlin
Country [53] 0 0
Germany
State/province [53] 0 0
Freiburg
Country [54] 0 0
Germany
State/province [54] 0 0
Heidelberg
Country [55] 0 0
Germany
State/province [55] 0 0
Stralsund
Country [56] 0 0
Germany
State/province [56] 0 0
Stuttgart
Country [57] 0 0
Germany
State/province [57] 0 0
Würzburg
Country [58] 0 0
Greece
State/province [58] 0 0
Ioannina
Country [59] 0 0
Greece
State/province [59] 0 0
Patras
Country [60] 0 0
Greece
State/province [60] 0 0
Voutes
Country [61] 0 0
Hungary
State/province [61] 0 0
Budapest
Country [62] 0 0
Italy
State/province [62] 0 0
Foggia
Country [63] 0 0
Italy
State/province [63] 0 0
Milano
Country [64] 0 0
Italy
State/province [64] 0 0
Padova
Country [65] 0 0
Italy
State/province [65] 0 0
Roma
Country [66] 0 0
Japan
State/province [66] 0 0
Aichi, Seto
Country [67] 0 0
Japan
State/province [67] 0 0
Fukui, Yoshida-gun
Country [68] 0 0
Japan
State/province [68] 0 0
Fukuoka, Fukuoka
Country [69] 0 0
Japan
State/province [69] 0 0
Hokkaido, Sapporo
Country [70] 0 0
Japan
State/province [70] 0 0
Shizuoka, Hamamatsu
Country [71] 0 0
Japan
State/province [71] 0 0
Tokushima, Tokushima
Country [72] 0 0
Japan
State/province [72] 0 0
Tokyo, Mitaka
Country [73] 0 0
Japan
State/province [73] 0 0
Tokyo, Ota-ku
Country [74] 0 0
Japan
State/province [74] 0 0
Tokyo, Shinjuku-ku
Country [75] 0 0
Malaysia
State/province [75] 0 0
Kajang
Country [76] 0 0
Netherlands
State/province [76] 0 0
Breda
Country [77] 0 0
Netherlands
State/province [77] 0 0
Rotterdam
Country [78] 0 0
New Zealand
State/province [78] 0 0
Christchurch
Country [79] 0 0
Norway
State/province [79] 0 0
Oslo
Country [80] 0 0
Poland
State/province [80] 0 0
Bialystok
Country [81] 0 0
Poland
State/province [81] 0 0
Swidnik
Country [82] 0 0
Poland
State/province [82] 0 0
Warsaw
Country [83] 0 0
Poland
State/province [83] 0 0
Warszawa
Country [84] 0 0
Spain
State/province [84] 0 0
L'Hospitalet de Llobregat
Country [85] 0 0
Spain
State/province [85] 0 0
Oviedo
Country [86] 0 0
Spain
State/province [86] 0 0
Pozuelo de Alarcón
Country [87] 0 0
Spain
State/province [87] 0 0
Santander
Country [88] 0 0
Taiwan
State/province [88] 0 0
Kaohsiung
Country [89] 0 0
Taiwan
State/province [89] 0 0
Taichung
Country [90] 0 0
Taiwan
State/province [90] 0 0
Taipei
Country [91] 0 0
United Kingdom
State/province [91] 0 0
Cottingham
Country [92] 0 0
United Kingdom
State/province [92] 0 0
Exeter
Country [93] 0 0
United Kingdom
State/province [93] 0 0
London
Country [94] 0 0
United Kingdom
State/province [94] 0 0
Manchester
Country [95] 0 0
United Kingdom
State/province [95] 0 0
Southampton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Boehringer Ingelheim
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Adults 40 years of age and older with idiopathic pulmonary fibrosis (IPF) or 18 years and older with progressive pulmonary fibrosis (PPF) can participate in this study. Only people who have a chronic cough can take part. The purpose of this study is to find out how well BI 1839100 helps reduce coughing in people with IPF or PPF.

Participants who have IPF are put into 4 groups by chance. Participants in 3 groups get different doses of BI 1839100. Participants in 1 group get placebo. Placebo looks like BI 1839100 but does not contain any medicine. Participants take the treatment for 3 months. After 1 month of treatment, participants who take the highest dose will have coughing measured to find out if the medicine works. If it does not work, the study may be stopped. Participants who have IPF are in the study for slightly longer than 4 months. During this time, they visit the study site 7 times. This study will also measure the effects of BI 1839100 on coughing and lung function in a smaller group of people with PPF.

During the study, coughing is measured over 24 hours about once per month using a portable device given to participants to use during the study. Participants fill in questionnaires about their coughing. Doctors also perform breathing tests that measure how well the lungs are working at the site visits. Researchers compare the results between participants who take BI 1839100 and placebo. The doctors also regularly check participants' health and take note of any unwanted effects.
Trial website
https://clinicaltrials.gov/study/NCT06360094
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Boehringer Ingelheim
Address 0 0
Country 0 0
Phone 0 0
1-800-243-0127
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT06360094